Can a simple arthritis drug stop brain damage from cancer therapy?
NCT ID NCT04205838
First seen Feb 27, 2026 · Last updated May 10, 2026 · Updated 7 times
Summary
This study tested whether anakinra, a drug that calms the immune system, could prevent severe brain inflammation (called ICANS) in people receiving CAR T-cell therapy for large B-cell lymphoma that had returned or stopped responding to treatment. The trial enrolled 23 participants but was ended early. The goal was to see if giving anakinra alongside CAR T-cells could reduce dangerous neurological side effects without harming the cancer-fighting power of the therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
UC Davis Comprehensive Cancer Center
Davis, California, 95817, United States
-
UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, California, 90095, United States
Conditions
Explore the condition pages connected to this study.